12th PharmacovigilanceConference, London - Main contents
| date | January 30, 2019 |
|---|---|
| city | London |
| location | The Tower Hotel, LONDON  |
| organisation | Medicines for Europe |
ADVERTISING, EXHIBITION & SPONSORSHIP OPPORTUNITIES
In London for the very last time!
The Medicines for Europe annual Pharmacovigilance Conference is more than a traditional conference. It is a unique opportunity to learn about the latest trends, to engage with renowned experts and to personally develop as a healthcare professional.
The 12th Pharmacovigilance Conference will convene in London for the very last time, at The Tower Hotel on 30th January 2019.
You will once more have the opportunity to listen to and engage with leading experts, regulators and healthcare professionals, taking stock of the past year’s achievements and discussing the future direction of pharmacovigilance.
Contents
jQuery(document).ready(function($){ $("#team-7189 .team-items").owlCarousel({ items : 5, //10 items above 1000px browser width autoHeight:true, responsiveClass:true, responsive:{ 0:{ items:1, nav:true }, 600:{ items:2, nav:true }, 900:{ items:2, nav:true }, 1000:{ items:5, nav:true, } }, navText : ["",""], nav: true, }); });
Director General - Medicines for Europe
Adrian van den HovenDirector General - Medicines for Europe
Senior Pharmacovigilance Consultant, Vigifit
Wendy HuismanSenior Pharmacovigilance Consultant, Vigifit
Dutch Representative of the PRAC, Chair, Medicines Evaluation Board
Sabine StrausDutch Representative of the PRAC, Chair, Medicines Evaluation Board
Treatment Information and Access Director, Health Policy Advisor, EURORDIS
François HouyezTreatment Information and Access Director, Health Policy Advisor, EURORDIS
Professor in Regulatory Science, University of Copenhagen, DK
Marieke De BruinProfessor in Regulatory Science, University of Copenhagen, DK
VP, Global Head - Product Safety and Risk Management & Medical Information, EU QPPV, Mylan
Balwant HeerVP, Global Head - Product Safety and Risk Management & Medical Information, EU QPPV, Mylan
PRAC Vice Chair, BfArM
Martin Huber (Dr.)PRAC Vice Chair, BfArM
Head of Signal & Risk Management, Gedeon Richter
Alexandra SzabóHead of Signal & Risk Management, Gedeon Richter
Senior Adviser Pharmacovigilance, Novartis Global Drug Development and Senior Visiting Research Fellow, Dept of Pharmacy, Pharmacology & Postgraduate Medicine, University of Hertfordshire
David LewisSenior Adviser Pharmacovigilance, Novartis Global Drug Development and Senior Visiting Research Fellow, Dept of Pharmacy, Pharmacology & Postgraduate Medicine, University of Hertfordshire
Head of the Medical Department and QQPV, EudraVigilance Representative, Tecnimede
Augusto Filipe, Dr. MDHead of the Medical Department and QQPV, EudraVigilance Representative, Tecnimede
Head Global Pharmacovigilance and EudraVigilance EWG Representative, Gedeon Richter
Attila OláhHead Global Pharmacovigilance and EudraVigilance EWG Representative, Gedeon Richter
Medical Advisor and Deputy QPPV, Billev Pharma East
Jana Brajdih ČendakMedical Advisor and Deputy QPPV, Billev Pharma East
Principal Coordinator for Safety Assessment of Medicines and Croatian PRAC Alternate Member
Željana Margan KoletićPrincipal Coordinator for Safety Assessment of Medicines and Croatian PRAC Alternate Member
Inspector, INFARMED
Antonio AzevedoInspector, INFARMED
Head of GCP and PhV Inspectorate, Spanish Medicines and Medical Devices Agency (AEMPS)
Ernesto Vera-SanchezHead of GCP and PhV Inspectorate, Spanish Medicines and Medical Devices Agency (AEMPS)
Vice-Chairperson CMDh (NL) - CMDh Member/Senior Policy Adviser, MEB (NL)
Kora Doorduyn-van der StoepVice-Chairperson CMDh (NL) - CMDh Member/Senior Policy Adviser, MEB (NL)
Head Regulatory Competence Centre Europe, Sandoz
Caroline KleinjanHead Regulatory Competence Centre Europe, Sandoz
Head of Safety and Deputy EU QPPV, GlaxoSmithKline Consumer Healthcare R&D
Wendy Booth, BSc, MRPharmSHead of Safety and Deputy EU QPPV, GlaxoSmithKline Consumer Healthcare R&D
Clinical Development and Safety Director, Medicines for Europe
Susana Almeida, PhDClinical Development and Safety Director, Medicines for Europe
TBN
What can you expect from the Conference programme in 2019?
The morning sessions will provide the opportunity for conference attendees to catch up on all recent activities and to prepare themselves for upcoming milestones such as
-
-Data protection regulation and the impact on pharmacovigilance processes
-
-Finding out when the outcomes of measuring the impact of pharmacovigilance activities are expected and possible changes that might follow
-
-Better understanding the initiative on Patient Hearings with reflections from the generic and biosimilars point of view
-
-Changes in the signal detection process and what will happen after the pilot period ends
-
-Experience gained with the enhanced EudraVigilance, good practices and the way forward
Compliance and pharmacovigilance outside the pharmacovigilance department will be the centre of interest during the afternoon session.
We will have a look at the new trends for the digital era.
We will conclude by reporting on the progress of the HaRP (risk management plan worksharing) project.
Over the years, one of the key successes of this conference has been the ability to secure the continuing support of key regulators. Sessions will once more be open and interactive giving attendees the opportunity to raise challenging issues in an informal environment.
Secure your place at the conference!
We look forward to welcoming YOU on 30 January 2019 in London!
See here the list of companies/authorities/organisations present at the 2018 edition!
Follow the event on Twitter - #PHV19
See highlights from our 2018 event
Video
Photo Gallery
Press Release
Medicines for Europe is honored to be collaborating with the following partners to make this year’s conference
M: +44 (0) 7 562 87 68 73
For more information on advertising, exhibition and sponsorship packages:
M: +31 6 4119 0824
Media Requirements and Press Policy
For any other media enquiries:
P: +32 (0)2 533 20 11